Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Reproductive Health Services

 
In compliance with the decisions of the International Conference on Population and Development in 1994 on behalf of the Government of Lebanon, the “Reproductive Health Program” was established at the Ministry of Public Health and supported by the United Nations Population Fund (UNFPA) under the umbrella of primary health care with a clear strategy between 1998 and 2001. The program is still ongoing through its integration within the primary health care department.

The Ministry of Public Health / Primary Health Care Department in collaboration with UNFPA provides various services regarding reproductive health and family planning in agreement with the joint annual work plan signed between the two parties.

The health services can be summarized in the following categories:
  • Family planning
  • Safe motherhood and Newborn Health
  • Diagnostic & Preventive Check-ups
  • Screening for Reproductive system diseases and reproductive tract cancers

I. Reproductive Health Services
The primary health care department provides preventive services in order to improve the health of the family (women, children, youth and men) through:
  • Providing reproductive health medications and supplies through PHC centers, including 57 health centers / clinics outside the primary health care network, and providing reproductive health services to the displaced in order to improve women's health and prevent unwanted pregnancies.
  • Delivering reproductive health information to beneficiaries through awareness and education programs which are provided by the primary health care centers within and outside the centers.
  • Providing equipment that enables early detection of reproductive system diseases (early detection of breast cancer, cervical cancer).
  • Encouraging pregnant women to receive a minimum of 4 visits during pregnancy and one postnatal visit.
  • Developing the capacity of service providers in primary health care centers based on the clinical protocols for reproductive health.
  • Preparing governmental hospitals to receive emergency obstetric cases.
  •  Equipping governmental hospitals to receive high-risk pregnancies.
  •  Capacity building of service providers to deal with survivors of sexual violence and refer them to relevant associations.
  • Capacity building of service providers of provision of equipment for primary health care centers and hospitals to address cases of rape and refer survivors to the relevant associations.
 

II. Antenatal and Postnatal Care Services:
The primary health care department offers as well antenatal and postnatal care services for pregnant Lebanese and non-Lebanese women across Lebanon as part of the reproductive health services. These services were supported by the formulation of the ‘’Service Delivery Guidelines’’, which were followed by consecutive training for primary health care (PHC) centers’ staff across Lebanon upon implementation.

The antenatal and postnatal care services offered by the PHC centers consist of the following:
All pregnant women visiting the centers should receive:
  1.  Minimum of 4 antenatal care services
  2.  2 Echography during pregnancy
  3.  1 postnatal visit
  4.  Coverage of vaccination for newborn of followed up mothers (according to the National Vaccination Calendar)
  5.  Provision of Reproductive Health drugs and supplies to all PHC centers, in addition to 64 Reproductive Health dispensaries supported by International NGOs to serve the displaced Syrians.
 

III. Service Delivery Guidelines for Reporoductive Health Care:
MoPH with the support of UNFPA and in collaboration with the Lebanese Society of Obstetrics & Gynecology (LSOG) launched " The Revised Version of the Service Delivery Guidelines for Reproductive Health" in June 2015, which aimed at improving the knowledge and skills of service providers, in order to ensure the provision of reproductive health services that meet women's, men's and youth's needs in Lebanon.

Accordingly, the first phase of training took place from July to September, with 275 physicians and health care workers, including: 160 paramedical specialties, 88 medical and 27 humanitarian actors.

The training aims to improve the knowledge, skills and confidence of health workers to ensure that reproductive health needs of women, men adults and youth are met in normal setting and in the case of crises.
 
IV. Project Reports:
    1
    ...
ATC Name B/G Ingredients Dosage Form Price
A05AA04 OCALIVA B Obeticholic acid - 10mg 10mg Tablet, film coated 224,503,943 L.L
A05AA04 OCALIVA B Obeticholic acid - 5mg 5mg Tablet, film coated 224,503,943 L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 300mg/10ml 300mg/10ml Injectable concentrate for solution L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 300mg/10ml 300mg/10ml Injectable concentrate for solution 547,517,314 L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 920mg/23ml 920mg/23ml Injectable solution 1,095,034,629 L.L
J06BA02 OCTAGAM BioHuman Human normal immunoglobulin G - 50mg/ml 2.5g/50ml Injectable solution 19,540,934 L.L
J06BA02 OCTAGAM BioHuman Human normal immunoglobulin G - 50mg/ml 5g/100ml Injectable solution 37,672,334 L.L
J06BA02 OCTAGAM BioHuman Human normal immunoglobulin G - 50mg/ml 10g/200ml Injectable solution 74,515,099 L.L
J06BA02 OCTAGAM 10% BioHuman Human normal immunoglobulin G - 10% 5g/50ml Injectable solution 37,672,334 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 250IU 250IU Injectable lyophilised powder for solution+diluent 13,247,110 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 500IU 500IU Injectable lyophilised powder for solution+diluent 26,495,478 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 1,000IU 1,000IU Injectable lyophilised powder for solution+diluent 46,817,511 L.L
B02BD04 OCTANINE F BioHuman Plasma coagulation factor IX, human - 500IU 500IU Injectable freeze dried powder + diluent 31,425,075 L.L
B02BD01 OCTAPLEX BioHuman Prothrombin complex, human (PPSB) - 500IU 500IU Injectable powder for solution+diluent 35,220,164 L.L
A04AA01 ODNATRON G Ondansetron (HCl dihydrate) - 4mg/2ml 4mg/2ml Injectable solution 880,217 L.L
A04AA01 ODNATRON G Ondansetron (HCl dihydrate) - 8mg/4ml 8mg/4ml Injectable solution 952,784 L.L
G03CA03 OESTRACLIN G Estradiol - 0.6mg/g 0.6mg/g Gel 448,843 L.L
G03CA03 OESTRODOSE B Estradiol (17 bêta estradiol anhydre) - 0.06% 0.06% Gel 642,357 L.L
L01EX09 OFEV B Nintedanib - 150mg 150mg Capsule, soft L.L
L01EX09 OFEV B Nintedanib - 100mg 100mg Capsule, soft 104,970,427 L.L
L01EX09 OFEV B Nintedanib - 150mg 150mg Capsule, soft 209,943,960 L.L
J01MA01 OFLACIN G Ofloxacin - 200mg 200mg Tablet, film-scored 602,041 L.L
J01MA01 OFLOMED G Ofloxacin - 200mg 200mg Tablet, film-scored 601,530 L.L
S02AA16 OFLOMED G Ofloxacin - 3mg/ml 3mg/ml Drops solution 317,403 L.L
S01AE01 OFLOX B Ofloxacin - 3mg/ml 0.3% Drops solution 366,869 L.L
S01AE01 OFLOX B Ofloxacin - 0.3% 0.3% Drops solution 366,869 L.L
L01FD01 OGIVRI BioTech Trastuzumab - 440mg 440mg Injectable lyophilised powder 80,027,615 L.L
N05AH03 OLANZAMED G Olanzapine - 5mg 5mg Tablet 665,522 L.L
N05AH03 OLANZAMED G Olanzapine - 20mg 20mg Tablet 3,941,938 L.L
N05AH03 OLANZAMED G Olanzapine - 10mg 10mg Tablet 902,294 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026